Company profile

Ticker
FCSC
Exchange
CEO
John M. Maslowski
Employees
Incorporated in
Location
Fiscal year end
Former names
American Financial Holding Inc, Isolagen Inc
SEC CIK
IRS number
870458888

FCSC stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Nov 19
7 Dec 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 1.02M 21.79M 0 0
Net income -7.2M 11.74M -3.67M -1.62M
Diluted EPS -0.76 1.12 -0.4 -0.14
Net profit margin -707% 53.89%
Operating income -4.36M 13.57M -3.86M -3.23M
Net change in cash -6.93M 2.38M -3.11M -1.68M
Cash on hand 6.77M 13.7M 11.32M 14.43M
Cost of revenue 1.69M 5.17M 0
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 0 0 355K 492K
Net income -10.28M -16.24M -15.29M -34.45M
Diluted EPS -1.45 -6.67 -1.18 -0.85
Net profit margin -4308% -7003%
Operating income -12.39M -18.98M -26.48M -37.41M
Net change in cash -2.99M -98K -11.75M -8.23M
Cash on hand 14.43M 17.42M 17.52M 29.27M
Cost of revenue 0 697K 722K

Financial data from company earnings reports

Financial report summary

?
Risks
  • Failure to complete the Merger could negatively impact the price of our common stock, as well as our future business and financial results.
  • The Merger Agreement limits our ability to pursue alternatives to the Merger and may discourage other companies from trying to acquire us for greater consideration than what CCP Holdings has agreed to pay.
  • The CCP License Agreement is important to our business. If we or CCP fail to adequately perform under the CCP License Agreement, or if we or CCP terminate the CCP License Agreement, the development and commercialization of FCX-007 would be delayed or terminated and our business would be adversely affected.
Management Discussion
  • Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • We are a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. We are utilizing our proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease.  Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas.  We target the underlying cause of disease by using fibroblast cells from a patient’s skin and genetically modifying them to create localized therapies that are compatible with the unique biology of the patient (i.e., which are autologous).
  • Our pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA). We are also developing FCX-013 for the treatment of moderate to severe localized scleroderma. Currently, all of our research and development operations and focus are on gaining regulatory approvals to commercialize our gene therapy candidates in the United States; however, we may seek to expand into international markets in the future.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accuracy, acquire, acquired, affirm, al, allege, alleged, appraisal, arising, assert, Braschuk, Burnaska, challenging, competing, complaint, complying, confidentiality, counsel, Court, Del, Delaware, demanding, detrimental, discourage, District, employment, entry, fact, false, forbear, Franchi, improperly, injunction, Joe, Kaboom, Kapital, lawsuit, Mascara, Master, merge, merit, misleading, MSD, multiplied, notification, NRM, Opportunity, Pharmaceutical, plaintiff, preliminary, premium, prohibition, promulgated, proxy, publicly, purported, purpose, pursuit, recommend, recommendation, refrain, regular, signature, soliciting, Southern, spent, styled, survive, surviving, tender, vi, vigorously, violated, waived, withdraw, withhold, York
Removed: comparable